Comparison of Biocompatibility of MTA with 3Mixtatin

Abstract

3Mixtatin is a novel endodontic material, which is recently has been used in vital pulp therapy procedures. It is composed of 3Mix (a combination of metronidazole, minocycline, and ciprofloxacin; TAP) and statin as an odontoblastic/osteoblastic inducer material. The purpose of this study is to present the biocompatibility of 3Mixtatin in different concentrations. Methods: In this in-vitro study, A549 adenocarcinoma cells were exposed to 0.01, 0.05, 0.1, 0.5 and 1 mg/mL concentrations of 3Mixtatin. MTT assay was used to determine the cytotoxicity of these concentrations in comparing with MTA as gold standard material. Results: With the exception to 0.01 mg/ml and 0.05 mg/ml concentrations over a period of 72hours, other groups had a significant difference with control group (P<0.05) after 24 hours. Data were analyzed using one-way ANOVA (p<0.05). Conclusion: The percentage of cell viability was correlated with the concentration of 3Mixtatin and was lower than that MTA. Collectively, MTA and low concentrations of 3Mixtatin both can be used clinically in the treatment of direct pulp therapy, indirect pulp therapy and pulpotomy of primary molars.